Innotive Diagnostics (InnotiveDx) today announces theappointment of Andrew Sails, PhD as Director of Research and Development.

Andrew brings over 30 years of experience in microbiologyand in vitro diagnostic development, including at Public Health England. Untilrecently, he was Chief Technical Manager at Cambridge Life Sciences. Beforethat, he was Director of Microbiology at ODx Innovations, a company that was alsodeveloping a UTI diagnostic system before it ceased trading.

Will Wijnberg, Chief Executive Officer of InnotiveDx,said: “We are thrilled that Andrew is joining the team at InnotiveDx. Weare building a world class team and Andy is a great addition. He bringsconsiderable experience in UTI diagnostic development and validation, whichwill be critical as we test our late-stage prototype system over the next 12months.

Andrew Sails, Director of Research and Development of InnotiveDx,said: “InnotiveDx is an exciting company, backed by impressive science andan excellent team. I am thrilled to have joined at such a pivotal time, as itbegins to test and enhance its diagnostic system. The market need for a rapid urinarytract infection (UTI) diagnostic system is huge and I look forward to playing apart in bringing this much-needed system to market and the contribution thiswill have to improving antimicrobial stewardship.  

About InnotiveDx

InnotiveDx is a privately owned medical device companydeveloping a revolutionary urinary tract infection (UTI) diagnostic system thatwill diagnose a UTI and provide antimicrobial susceptibility test resultswithin 60 minutes. UTIs are commonly seen in clinical practice and affecthundreds of millions of people per year worldwide, of which more than 71% arewomen. Currently, most UTI prescriptions are given on an empiric basis leadingto significant rates of treatment failure, costing global healthcare systemsbillions of dollars annually and contributing to antimicrobial resistance.

‍